
Background Community pharmacy practice is modernizing to a patient-centered model of care, where the implementation of patient care services, evolving business models, and a consistent approach to the way payment for services occurs is essential to long-term sustainability. Objective To describe the development, implementation, and growth of a community pharmacy clinically integrated network (CIN) for pharmacist-provided patient care services throughout Pennsylvania. Practice description The Pennsylvania Pharmacists Care Network (PPCN) is an affiliated chapter of CPESN USA, a CIN providing nationwide support, infrastructure, and best practice alignment. PPCN's collaboration with colleges/schools of pharmacy, the state pharmacy association, CPESN USA, and other key partners have been essential to network formation. Network pharmacies must meet a minimum set of patient care requirements including documentation of patient care services through an electronic care plan, using the Pharmacist eCare Plan (PeCP) standard. Practice innovation PPCN partners with health payors in contracting patient care services on behalf of participating pharmacies. Payor contracts include fee-for-service and value-based care reimbursement structures. Regular communication with payor partners and network pharmacies help ensure quality and achievement of programmatic goals. Evaluation methods Descriptive statistics were used to characterize patient care service PeCP data between September 2017 and December 2025. Results Between September 1, 2017, and December 31, 2025, pharmacists provided 198,626 patient encounters through 7 payor programs. January 1, 2021, marked the launch of additional payor programs and the inclusion of data collection through a more comprehensive PeCP report. During this time, over 200 pharmacies and pharmacy teams engaged 25,371 unique patients through a payor program. Conclusion The development and growth of PPCN has led to a steady volume of payor contracts for a wide variety of pharmacist-provided patient care services. Collaboration among different stakeholders is vital to network development, and payment mechanisms are essential to sustain and grow network services.
Background The Medicare Prescription Payment Plan (MPPP) enables beneficiaries to convert prescription out-of-pocket (OOP) costs into a capped monthly bill. Clinicians and patients lack practical, mechanism-based guidance on when MPPP meaningfully smooths costs versus when it provides limited or counterproductive value. Quantifying conditions under which MPPP improves monthly affordability and predictability, to derive simple, portable rules for clinical counseling, has not been systematically evaluated. Objective Using diabetes regimens as a clinically familiar price-tier model, quantify how MPPP changes monthly payments across plan designs, medication regimens, fill cadences, and enrollment dates, as well as identify mechanism-based patterns that may inform patient-specific counseling. Method Medication regimens comprised a generic diabetes backbone and brand-name add-ons using Jardiance (a mid-priced proxy) and Ozempic (a high-priced proxy), administered alone or in combination, to simulate monthly OOP costs with and without enrolling in MPPP, under 4 canonical Part D plan designs. We modeled 30- versus 90-day fills and MPPP enrollment in January, July, or October. Monthly payment trajectories were the foundational outcomes; 6 study-developed descriptive measures summarized first-bill relief, peak-payment reduction, variability, and late-year payment concentration. Results In a deductible/co-insurance plan with brand therapy, MPPP produced payment-smoothing benefits (peak bill reduction (PBR)% ≈ 40 to 75%, first-bill relief% ≈ 40 to 80%, variability reduction (VR)% ≈ 40 to 60%, December shock index (DSI) ≈1.0–1.4), largest for Ozempic-like or two-brand regimens and with 90-day fills. July starts retained these gains, and October starts still yielded meaningful improvements under a 90-day supply. In flat-copayment plans, generic-only or single mid-priced brand regimens showed PBR ≈ 0 and VR% ≤ 0 with higher late-year concentration (year-end share% ≥ 45, DSI ≥ 2), with exceptions for high-cost two-brand regimens on 90-day fills. Conclusions MPPP is most effective when paired with deductibles or co-insurance plans for mid- to high-priced brand-name medications; even mid- and late-year starts can be advantageous. In flat-copayment plans or generic-only regimens, benefits are minimal, and late-year concentration can worsen. Lower early payments may be followed by MPPP bills that exceed the corresponding standard Part D payments later in the year. These mechanism-anchored rules generalize beyond diabetes to other conditions with similar price tiers under Part D.
Background As recognized members of the mental health care team, pharmacists are uniquely positioned to support use of prescription digital therapeutics (DTx) for schizophrenia. However, their specific role in care is yet to be clarified. Objective To develop recommendations for how pharmacists can embed prescription DTx within health care systems and improve access to and engagement with these treatments. Methods A modified Delphi approach captured U.S. pharmacists' perspectives on prescription DTx for schizophrenia. A 4-member expert steering committee developed a consensus framework on scale, access, and data to inform the creation of an online survey. Ten pharmacy experts with mental- and digital-health experience (average experience: 23.7 years) completed the survey and its results were used to formulate 24 Delphi panel questions (17 yes/no; 7 multiple-choice). Pharmacy experts and steering committee members (N = 14) voted on the Delphi panel questions. Consensus was defined as ≥70% agreement. Questions failing to reach consensus statements in round 1 were discussed and subjected to a second vote. If consensus was not achieved after round 2, “no consensus achieved” was documented and the highest-voted category was noted. Results Consensus statements were achieved on 20/24 (83%) questions (scale, n = 8; access, n = 10; and data, n = 2). Of these, 17/20 (85%) questions achieved consensus statements after 1 voting round; 3/20 (15%) required a second round. Four questions did not achieve consensus statements. The accepted statements informed recommendations regarding pharmacists' involvement in optimizing prescription DTx use for schizophrenia. Conclusion Recommendations included: pharmacists can facilitate expanding scale by supporting integration of prescription DTx into pharmacy systems and addressing adoption barriers through prescriber education and partnerships; support access by being involved when a prescription DTx is introduced to a patient; and leverage clinical data that are a priority to stakeholders to drive awareness, usage, and adoption.
Background Medication adherence is critical for effective management of chronic diseases among older adults. While nonadherence is common in India, limited qualitative research has explored how older adults, pharmacists, and physicians perceive the behavioral, communication-related, and contextual factors influencing long-term medicine use. Objectives To explore medication adherence among older adults with chronic illness by examining the perspectives of patients, pharmacists, and physicians on behavioral, communication-related, and contextual factors influencing long-term medicine use. Methods This qualitative study was conducted as part of a larger community-based mixed-methods study in urban and rural areas of western India. In-depth interviews were conducted with 40 participants, including 20 older adults (≥60 years), 13 pharmacists, and 7 physicians. Participants were selected purposively. Interviews were audio-recorded, transcribed verbatim, translated where necessary, and analyzed using Braun and Clarke's inductive thematic analysis. Triangulation across participant groups enhanced the credibility of the findings. Results Six interconnected themes emerged, highlighting how medication adherence is shaped by symptom-based understanding of illness, daily routines, family support, communication experiences, health care interactions, and structural constraints. Absence of symptoms was frequently interpreted as disease control, contributing to both intentional and unintentional nonadherence. Trust in health care providers, clear explanations, and pharmacist-led counseling facilitated adherence, whereas communication gaps, financial burden, and polypharmacy acted as barriers. Participants described using practical self-management strategies, including medication routines, reminder systems, and family support, to sustain long-term medicine use. Conclusion Medication adherence among older adults is influenced by interconnected behavioral, social, communicative, and structural factors. Strengthening patient education, counseling, and provider–patient communication, while addressing financial and treatment-related barriers, may improve long-term adherence. Multidisciplinary, patient-centered approaches are needed to support chronic disease management in aging populations.